Entering its first major global partnership, privately held Affymax Inc. turned to its Japanese partner Takeda Pharmaceutical Co. Inc. to grant the rest-of-the-world rights to its anemia drug, Hematide. (BioWorld Today)

In an effort to focus on its preclinical targeted therapeutics, SuperGen Inc. decided to sell the North American rights to Nipent and SurfaceSafe to Mayne Pharma Ltd. in a deal worth $34 million. (BioWorld Today)

Completing its planned exit from small-molecule development, Celera Genomics sold its cathepsin S inhibitor program to Schering AG in a deal worth up to $365 million. (BioWorld Today)

Less than three months after signing its first major preclinical deal focused on infectious disease, PTC Therapeutics Inc. topped it with a new cardiovascular collaboration worth up to $345 million with CV Therapeutics Inc. (BioWorld Today)